Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559990 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19593004 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12559581 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL203259 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15317886 | 0.98 | CYP3A4 (0.78) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12559637 | 0.98 | CYP3A4 (0.78) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12598272 | 0.97 | CYP3A4 (0.74) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19326694 | 0.96 | CYP3A4 (0.73) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19326695 | 0.96 | CYP3A4 (0.73) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12559589 | 0.95 | CYP3A4 (0.73) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586329-A | Crystalline forms of hepatitis c inhibitors and their use in medicine | 广东东阳光药业股份有限公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2024032718-A1 | CRYSTAL FORM OF HEPATITIS C INHIBITOR AND USE THEREOF IN DRUG | 广东东阳光药业股份有限公司 | 2024-02-15 | — | — | WO | claimed |
| WO-2024017234-A1 | SALT OF HCV INHIBITOR, CRYSTAL FORM OF SALT, PHARMACEUTICAL COMPOSITION OF SALT, AND USE OF SALT | 广东东阳光药业股份有限公司 | 2024-01-25 | — | — | WO | claimed |
| CN-117417327-A | Salt of HCV inhibitor, crystalline form of salt, pharmaceutical composition thereof and use thereof | 广东东阳光药业股份有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-110958880-B | Solid dispersion preparation | 东莞东阳光太景医药研发有限责任公司 | 2023-08-08 | — | — | CN | claimed |
| EP-4005560-B1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12522570-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12297164-B2 | Benzidine compound and application thereof | GUANGZHOU IMD THERAPEUTICS CO., LTD. (CN) | 2025-05-13 | — | — | US | disclosed |
| EP-4480544-A2 | IMMUNOMODULATORY COMPOSITIONS ANDMETHODS OF USE THEREOF | Agrawal, Babita (CA) | 2024-12-25 | — | — | EP | disclosed |
| CN-112074506-B | 4' -Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses | 埃默里大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-118477090-A | 4' -Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses | 埃默里大学 | 2024-08-13 | — | — | CN | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| WO-2011028596-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297164-B2 | Benzidine compound and application thereof | RORC, RORB, RORA | CYP3A4 166/4885CYP2C9 47/4885KCNH2 1322/4885 |
| US-20110152237-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | CYP3A4 52/4885CYP2C9 40/4885KCNH2 2695/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | CYP3A4 4409/4885CYP2C9 4746/4885KCNH2 4348/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885KCNH2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.